There is a lot of noise about artificial intelligence in healthcare. Most of it focuses on clinical applications: diagnosis support, imaging analysis, drug discovery. These are real and important. But there is a quieter set of changes happening at the operational layer of healthcare, in how medical products actually move from manufacturers through distribution to the people who dispense them. That layer is less dramatic to write about, but the scale of inefficiency it carries is substantial.
This article is about what machine learning and smarter search are actually doing to pharmaceutical procurement in the B2B context. Not what they theoretically might do in ten years, but what they are doing now, including what we are building at Covalenty and what we are not yet doing but want to.
The Matching Problem in Pharmaceutical Distribution
At its core, pharmaceutical distribution is a matching problem. A pharmacy needs a specific medication at a specific quantity within a specific time window. A distributor has some quantity of that medication, priced at some amount, available for delivery in some number of days. The challenge is that neither the pharmacy nor the distributor has perfect visibility into each other's situation. A pharmacy does not know what every distributor has in stock. A distributor does not know which pharmacies are actively looking to buy right now and at what price they are willing to buy.
Traditional matching in this market happens through sales rep relationships. A distributor assigns reps to a region, those reps build personal relationships with pharmacy buyers, and orders flow through those relationships. This works, but it is slow, it is information-poor, and it systematically disadvantages smaller buyers who cannot justify a dedicated rep's time.
The matching problem gets harder when you add pharmaceutical complexity. A pharmacy searching for "metformin" might mean metformin 500mg, or 850mg, or 1000mg, in any of several presentations, from any of several manufacturers with valid generic registration. These are not equivalent products even if the generic name is the same. A search system that does not understand the product taxonomy of pharmaceutical regulation will return bad matches and waste the buyer's time.
Search That Understands Pharmaceutical Nomenclature
The first place where machine learning helps is in search itself. Pharmacies in Brazil search for products using a mix of brand names, generic names, partial ANVISA registration numbers, and informal trade names. A pharmacy looking for a generic statin might type "atorva" and expect the system to return atorvastatina products. A simpler keyword search returns only exact matches. A system that has been trained on the relationship between these terms returns useful results.
Building this requires training data that reflects how pharmacy professionals actually search, not how product databases are structured. Our search index was built by starting with ANVISA's registered product database and then expanding it with the real search terms that users in our pilot typed when looking for the same products. The gap between how products are officially named and how buyers actually search for them is significant, and bridging it is more work than it looks.
This is a narrow application of language modeling to a specific domain problem. We are not saying we have built a general pharmaceutical intelligence system. We have built a search layer that works well for the specific nomenclature patterns of Brazilian pharmaceutical retail procurement.
Ranking and Relevance: Not Just Price
When a pharmacy searches for a product and sees results from multiple distributors, the order in which those results appear matters. The naive ranking is price, lowest to highest. But price alone is not always the most relevant signal.
A pharmacy that has ordered from a specific distributor before and received product on time, in correct condition, has a reason to value that distributor's offers differently than an offer from a distributor they have never used. A pharmacy that needs next-day delivery should see that distributor's results ranked higher even if their price is slightly higher than a distributor that takes three days to deliver. A pharmacy running low on a product that goes into a critical medication category might weight availability more than a pharmacy with adequate stock.
Incorporating these signals into ranking is the direction we are working toward. The current version of Covalenty's search shows results with price, delivery time, and stock status displayed clearly so that the buyer can sort and filter. The next step is contextual ranking that learns from individual pharmacy behavior over time: what they ordered, what delivery windows they preferred, which distributors they came back to. This is machine learning in a classic collaborative-filtering sense applied to a B2B procurement catalog.
Inventory Signal and Demand Forecasting
The harder problem, which we are not yet solving fully, is predicting when a pharmacy will need to reorder. Most independent pharmacies in Brazil do not have sophisticated inventory management systems. They know their stock has run low when the shelf gets empty or when a pharmacist notices. Reorder decisions are made reactively rather than proactively.
A platform that has visibility into order history across multiple pharmacies can in principle identify patterns: product X tends to be reordered every N weeks by pharmacies with a certain dispensing profile, and a pharmacy that has not ordered it in 2N weeks is either running low or sourcing it elsewhere. This kind of demand signal, even if noisy, is more useful than no signal at all for a distributor trying to forecast buying demand.
Building this requires data, and data requires users who have been on the platform long enough to generate meaningful order history. We are still in early days on this. What we can say is that the architecture we built anticipates this use case: order data is structured in a way that allows pattern analysis rather than just transaction recording.
The Healthcare-Specific Constraint Layer
Pharmaceutical B2B procurement cannot be treated like a general commodity marketplace. Every product has regulatory attributes that affect whether it can be bought, sold, and dispensed in specific contexts. Controlled substances require special handling at every stage. Cold chain products require temperature documentation. ANVISA product registrations have expiry dates, and a product whose registration has lapsed cannot legally be sold regardless of whether it is physically available.
A smart procurement system has to understand this constraint layer and enforce it without putting the burden on the buyer to check manually. Our product catalog is linked to ANVISA registration status. When a registration lapses, the product is flagged and should not appear as purchasable in search results. This is a backend data quality and pipeline problem more than a machine learning problem, but it is essential infrastructure for making the search results trustworthy in a regulated context.
What We Are Not Claiming
It would be easy to write an article that overstates where the technology currently is. We are not going to do that. The reality is that the intelligence layer in current pharmaceutical B2B procurement platforms, including ours, is relatively thin. The core value we provide is information visibility: making prices and availability visible in one place where they were previously scattered across phone calls. That is genuinely valuable, but it is not a fundamentally new technology. It is infrastructure that should have existed years ago and did not because the market structure did not create incentives to build it.
The machine learning applications are genuine but modest in scale. Better search nomenclature, smarter ranking, and the early stages of demand signal analysis: these are real and they improve the product. They are not going to replace the judgment that experienced pharmacy operators bring to managing their relationships and their stock. We are building tools to make that judgment faster and better-informed, not to replace it.
The more ambitious applications, like automated reorder recommendations at the individual pharmacy level or real-time demand forecasting that distributors can act on, require more data and more time on the platform. We are working toward them and we are building in the right direction. But we are doing so with a small engineering team in Sao Paulo, not a research division.
